Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Midostaurin in Newly Diagnosed FLT3 Mutated AML
NCT00651261Phase 3Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Apr 2008
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of midostaurin in acute myeloid leukemia (AML), sponsored by Cancer and Leukemia Group B. Started Apr 2008; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00651261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00651261.